TrialBMC cancer2019

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.

Françoise Rothé et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.